Valérie Leclair

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1745889/publications.pdf

Version: 2024-02-01

17 papers	300 citations	933264 10 h-index	17 g-index
18	18	18	398
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter. Current Rheumatology Reports, 2018, 20, 18.	2.1	65
2	Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Research and Therapy, 2020, 22, 5.	1.6	48
3	Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. PLoS ONE, 2016, 11, e0160753.	1.1	29
4	Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open, 2020, 6, e001357.	1.8	23
5	Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. Rheumatology, 2019, 58, 1214-1220.	0.9	22
6	Histopathological features of systemic sclerosis-associated myopathy: A scoping review. Autoimmunity Reviews, 2021, 20, 102851.	2.5	17
7	Autoantibody profiles delineate distinct subsets of scleromyositis. Rheumatology, 2022, 61, 1148-1157.	0.9	16
8	Successful Lung Transplantation in a Case of Rapidly Progressive Interstitial Lung Disease Associated with Antimelanoma Differentiation-associated Gene 5 Antibodies. Journal of Rheumatology, 2018, 45, 581-583.	1.0	15
9	Acute Coronary Syndrome in Idiopathic Inflammatory Myopathies: A Population-based Study. Journal of Rheumatology, 2019, 46, 1509-1514.	1.0	13
10	Polymyositis: does it really exist as a distinct clinical subset?. Current Opinion in Rheumatology, 2021, 33, 537-543.	2.0	13
11	Subsets in systemic sclerosis: one size does not fit all. Journal of Scleroderma and Related Disorders, 2016, 1, 298-306.	1.0	11
12	Recent clinical trials in idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2017, 29, 652-659.	2.0	11
13	Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of â€`scleromyositis'. Acta Neuropathologica, 2021, 142, 395-397.	3.9	7
14	Distribution and trajectory of direct and indirect costs of idiopathic inflammatory myopathies. Seminars in Arthritis and Rheumatism, 2021, 51, 983-988.	1.6	6
15	Letter in response to â€~Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors'. European Journal of Cancer, 2019, 112, 47-48.	1.3	2
16	Response to: ‴Time to personalise the treatment of anti-MDA-5 associated lung disease' by Lake et al. Annals of the Rheumatic Diseases, 2019, 78, e53-e53.	0.5	1
17	Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report. BMC Rheumatology, 2022, 6, 11.	0.6	1